Prilenia Therapeutics Development Ltd.

Prilenia Therapeutics has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of its neurodegenerative disease drug pridopidine in Europe a

Pridopidine, Prilenia Therapeutics ’ drug candidate for treating Huntington’s disease, and sebetralstat, KalVista Pharmaceuticals ’ investigational oral, on-demand therapy for hereditary angioedema,

The positive Phase III results and subsequent US approval of lecanemab for Alzheimer’s disease was reflected by a spike in enthusiasm for the central nervous system (CNS) space among the 90 or so resp

Coming off clinical development setbacks, including a failed effort to expand Ingrezza’s label into pediatric Tourette’s syndrome, Neurocrine Biosciences, Inc. reported positive R&D news to its share